Mitochondria-penetrating peptides conjugated to desferrioxamine as chelators for mitochondrial labile iron

Area of Science:

• Biochemistry
• Mitochondrial Biology
• Drug Development

Background:

• Desferrioxamine (DFO) is an iron chelator with poor cell penetration.
• Mitochondrial iron overload is implicated in various diseases.
• Targeting mitochondria requires specialized delivery strategies.

Purpose of the Study:

• To synthesize and characterize novel Desferrioxamine (DFO) conjugates (mtDFOs) designed for enhanced mitochondrial penetration.
• To evaluate the iron-binding capacity, antioxidant properties, cellular toxicity, and mitochondrial localization of these mtDFOs.
• To assess the potential of mtDFOs for ameliorating mitochondrial iron overload conditions.

Main Methods:

• Synthesis and purification of DFO conjugated to Mitochondria Penetrating Peptides (TAT49-57, 1A, SS02, SS20) via a succinic linker.
• Assessment of iron binding affinity and antioxidant capacity.
• In vitro toxicity assays using A2780 cells and IC50 determination.
• Mitochondrial localization studies using TAMRA-labeled conjugates.
• Evaluation of mitochondrial DNA (mtDNA) damage, cell cycle arrest, and apoptosis.

Main Results:

• The synthesized mtDFOs maintained strong iron binding and antioxidant capabilities.
• mtDFOs exhibited good mitochondrial localization (Rr +0.45 -+0.68) and relatively low toxicity to A2780 cells (IC50 40-100 μM).
• mtDFOs caused only modest mtDNA damage, and DFO-SS02 specifically inhibited mitochondrial superoxide formation, retaining peptide antioxidant activity.

Conclusions:

• Mitochondria-penetrating Desferrioxamine (mtDFO) conjugates are effective iron chelators with enhanced mitochondrial targeting.
• These novel compounds demonstrate a favorable safety profile and retain crucial biological activities.
• mtDFOs represent promising therapeutic candidates for managing diseases associated with mitochondrial iron overload.